


**Product Name** : PF-06651600  
**Cat. No.** : PC-62333  
**CAS No.** : 1792180-81-4  
**Molecular Formula** : C<sub>15</sub>H<sub>19</sub>N<sub>5</sub>O  
**Molecular Weight** : 285.351  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



## Biological Activity

Ritlecitinib (PF-06651600) is a novel potent, selective **JAK3** inhibitor with IC<sub>50</sub> of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2.

PF-06651600 inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models.

PF-06651600 selectively targets  $\gamma$ c cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNF $\alpha$  and IL-1 $\beta$  production in IL-27-primed macrophages.

## References

Telliez JB, et al. *ACS Chem Biol*. 2016 Dec 16;11(12):3442-3451.

Thorarensen A, et al. *J Med Chem*. 2017 Mar 9;60(5):1971-1993.

Robinette ML, et al. *Mucosal Immunol*. 2017 May 17. doi: 10.1038/mi.2017.38.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com